Alto Neuroscience, Inc. (ANRO)
NYSE: ANRO · Real-Time Price · USD
2.380
-0.070 (-2.86%)
At close: Jun 5, 2025, 4:00 PM
2.399
+0.018 (0.78%)
After-hours: Jun 5, 2025, 7:54 PM EDT
Alto Neuroscience Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
76
Market Cap
64.43M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | 210.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionANRO News
- 2 days ago - Alto Neuroscience Announces Acquisition of Novel Dopamine Agonist Combination Product Candidate, Adding Late-Stage Readout in Treatment Resistant Depression Within Current Cash Runway - Business Wire
- 7 days ago - Alto Neuroscience Presents Data at the 2025 American Society of Clinical Psychopharmacology Annual Meeting Reinforcing Safety and Tolerability Profile for ALTO-300 in Major Depressive Disorder - Business Wire
- 8 days ago - Alto Neuroscience to Participate in Upcoming Investor Conferences - Business Wire
- 22 days ago - Alto Neuroscience Reports First Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 5 weeks ago - Alto Neuroscience Presents New Data at the Society of Biological Psychiatry Annual Meeting Underscoring Precision Psychiatry Approach - Business Wire
- 6 weeks ago - Alto Neuroscience to Participate in the JonesResearch Virtual CNS Day - Business Wire
- 2 months ago - Alto Neuroscience Reports Full-Year 2024 Financial Results and Recent Business Highlights - Business Wire
- 3 months ago - The Schall Law Firm Invites Investors With Losses In Alto Neuroscience, Inc. To Join A Securities Fraud Investigation - Accesswire